Interestingly, these effects were PTH-independent, suggesting that Act-A may exert peculiar regulatory effects on bone metabolism and confirming the possibility to consider modulation of Act-A signaling as a new therapeutic strategy in the treatment of CKD-MBD [105]. This evidence concerns the gene ACTA1 and chronic kidney disease.